… Since SEER implemented a modification in the rules for coding localized stage prostate
cancer in 1983, we included in this study only case patients with localized stage prostate cancer …

… prostate cancer; PFS on next-line therapy (PFS 2; defined as the time from start date of first
further anticancer treatment of prostate cancer … further treatment of prostate cancer and quality …

… 3.1 Screening of a panel of prostate (cancer) cell lines for PARPi sensitivity In order to
identify prostate cancer cell lines sensitive to PARPi treatment, we performed a screening with a …

… a switch maintenance treatment with orteronel, an oral inhibitor of androgen biosynthesis,
prolongs disease control in men with metastatic castration-resistant prostate cancer (mCRPC) …

… prostate cancer (mCRPC) and is a standard therapy in this setting. Previous androgen
deprivation therapy (… the efficacy of ADT maintenance during chemotherapy in castration-resistant …

… the first study of temsirolimus maintenance therapy in 21 CRPC patients … prostate cancer
models, and the favorable safety profile of rapalog mTORis. Temsirolimus maintenance therapy …

… steroidogenesis within prostate tumors and the maintenance of … prostate tissue, untreated
primary prostate cancer, metastases from patients with castration-resistant prostate cancer, and …

… for the management of advanced prostate cancer provides a range of treatment options
with notable benefits for men with metastatic castration-resistant prostate cancer (mCRPC). At …

… them with maintenance therapy. … maintenance therapy for prostate cancer is particularly
well suited because of the efficacy of conventional treatments, such as hormone ablative therapy…

… local therapy and has potential as a molecular marker for clinical outcome in prostate cancer.
… in predicting outcome after therapy for patients undergoing surgery for prostate cancer. …